leadf
logo-loader
viewPsyence Group Inc
(
CSE:PSYG
)

Psyence taps AstraZeneca veteran Neil Maresky as new CEO to impact mental health with psychedelics

Psyence Group Inc. (CSE: PSYG) new CEO Dr. Neil Maresky joins Proactive to talk about his new appointment and his qualifications, including spending more than a decade at AstraZeneca Canada as Vice President of Scientific Affairs.

Maresky, a South African trained doctor, says he joined the psychedelics-focused life sciences group because of its ability to potentially impact mental health including depression, anxiety, PTSD, and end-of-life care.

Quick facts: Psyence Group Inc

Follow
CSE:PSYG

Price: 0.195 CAD

Market Cap: $16.68 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Psyence Group launches its functional mushroom products under the GOODMIND...

Psyence Group Inc (CSE:PSYG) (CSE:PSYG)'s Tony Budden caught up with Proactive New York to discuss the the international biotechnology company with operations in South Africa's launch of its range of functional mushroom products under the GOODMIND banner. Budden says the GOODMIND formula...

on 23/8/21

2 min read